RSLCX Mutual Fund Forecast & Price Targets

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

RSLCX Analyst Rating

Moderate Buy

515 Buy

282 Hold

17 Sell

Based on the consensus analyst ratings on 814 stocks held in RSLCX.

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

RSLCX Analyst Price Target

Average Price Target

$68.12

Based on 814 Wall Street analysts offering 12 month price targets to American Funds - SMALLCAP World Fund Inc Class R-3 Shares holdings in the last 3 months. The average price target is $68.12 with a high forecast of $77.63 and a low forecast of $59.39. The average price target represents a 14.96% change from the last price of $59.26.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"57":"$57","78":"$78","62.25":"$62.3","67.5":"$67.5","72.75":"$72.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":77.627,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$77.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":68.123,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$68.12</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":59.392,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$59.39</span>\n  </div></div>","useHTML":true}}],"tickPositions":[57,62.25,67.5,72.75,78],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n              \n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.96,65.0113076923077,66.06261538461538,67.11392307692307,68.16523076923077,69.21653846153846,70.26784615384615,71.31915384615384,72.37046153846154,73.42176923076923,74.47307692307692,75.5243846153846,76.57569230769231,{"y":77.627,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.96,64.28023076923077,64.60046153846154,64.9206923076923,65.24092307692308,65.56115384615384,65.88138461538462,66.2016153846154,66.52184615384616,66.84207692307693,67.16230769230769,67.48253846153847,67.80276923076923,{"y":68.123,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,63.96,63.60861538461538,63.25723076923077,62.905846153846156,62.55446153846154,62.20307692307693,61.85169230769231,61.50030769230769,61.148923076923076,60.797538461538466,60.44615384615385,60.09476923076923,59.74338461538462,{"y":59.392,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":62.22,"date":1717372800000,"info":"<div>Price: <b>$62<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":61.46,"date":1719792000000,"info":"<div>Price: <b>$61<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":62.44,"date":1722470400000,"info":"<div>Price: <b>$62<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":62.85,"date":1725321600000,"info":"<div>Price: <b>$63<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":65.08,"date":1727740800000,"info":"<div>Price: <b>$65<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":63.78,"date":1730419200000,"info":"<div>Price: <b>$64<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":66.63,"date":1733097600000,"info":"<div>Price: <b>$67<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":62.72,"date":1735776000000,"info":"<div>Price: <b>$63<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":63.64,"date":1738540800000,"info":"<div>Price: <b>$64<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":60.49,"date":1740960000000,"info":"<div>Price: <b>$60<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":58.86,"date":1743465600000,"info":"<div>Price: <b>$59<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":59.94,"date":1746057600000,"info":"<div>Price: <b>$60<b/></div>","marker":{"enabled":true,"symbol":"circle"}},{"y":63.96,"date":1748822400000,"info":"<div>Price: <b>$64<b/></div>","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$77.63

Average Price Target$68.12

Lowest Price Target$59.39

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

RSLCX Stocks With Highest Upside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ARTV

Artiva Biotherapeutics, Inc.

5 Buy

0 Hold

0 Sell

Strong Buy

$19.00

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ALLO

Allogene Therapeutics

10 Buy

3 Hold

0 Sell

Strong Buy

$7.75

xxxxxxxxxxxxxxxxxxxxxxxxxxx

NTLA

Intellia Therapeutics Inc

16 Buy

4 Hold

1 Sell

Moderate Buy

$30.44

xxxxxxxxxxxxxxxxxxxxxxxxxxx

GPCR

Structure Therapeutics, Inc. Sponsored ADR

10 Buy

0 Hold

0 Sell

Strong Buy

$78.56

xxxxxxxxxxxxxxxxxxxxxxxxxxx

BHVN

Biohaven Ltd.

9 Buy

1 Hold

0 Sell

Strong Buy

$56.57

RSLCX Stocks With Highest Downside Potential

xxxxxxxxxxxxxxxxxxxxxxxxxxx

4919

Milbon Co

0 Buy

1 Hold

0 Sell

Hold

$2,922.94

xxxxxxxxxxxxxxxxxxxxxxxxxxx

MAXHEALTH

Max Healthcare Institute Ltd

0 Buy

0 Hold

1 Sell

Moderate Sell

$615.00

xxxxxxxxxxxxxxxxxxxxxxxxxxx

MRF

MRF Limited

0 Buy

0 Hold

1 Sell

Moderate Sell

$90,667.00

xxxxxxxxxxxxxxxxxxxxxxxxxxx

ATE

ALTEN

1 Buy

1 Hold

0 Sell

Moderate Buy

$91.00

xxxxxxxxxxxxxxxxxxxxxxxxxxx

GAW

Games Workshop

1 Buy

0 Hold

0 Sell

Moderate Buy

$11,850.00

RSLCX Mutual Fund FAQ

What is RSLCX’s average 12-month price target, according to analysts?

Based on analyst ratings, American Funds - SMALLCAP World Fund Inc Class R-3 Shares’s 12-month average price target is 68.12.

What is RSLCX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for RSLCX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is RSLCX a Buy, Sell or Hold?

American Funds - SMALLCAP World Fund Inc Class R-3 Shares has a consensus rating of Moderate Buy which is based on 515 buy ratings, 282 hold ratings and 17 sell ratings.

What is American Funds - SMALLCAP World Fund Inc Class R-3 Shares’s price target?

The average price target for American Funds - SMALLCAP World Fund Inc Class R-3 Shares is 68.12. This is based on 814 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $77.63 ,the lowest forecast is $59.39. The average price target represents N/A Increase from the current price of N/A.

What do analysts say about American Funds - SMALLCAP World Fund Inc Class R-3 Shares?

American Funds - SMALLCAP World Fund Inc Class R-3 Shares’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 814 Wall Streets Analysts.

How can I buy shares of RSLCX?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing